PMID- 25721424
OWN - NLM
STAT- MEDLINE
DCOM- 20170317
LR  - 20170317
IS  - 1442-2050 (Electronic)
IS  - 1120-8694 (Linking)
VI  - 29
IP  - 4
DP  - 2016 May
TI  - Value of the Gastroesophageal Reflux Disease Questionnaire (GerdQ) in predicting 
      the proton pump inhibitor response in coronary artery disease patients with 
      gastroesophageal reflux-related chest pain.
PG  - 367-76
LID - 10.1111/dote.12329 [doi]
AB  - Chest pain experienced by patients with coronary artery disease can be partly due 
      to gastroesophageal reflux-induced chest pain (GERP). Empirical proton pump 
      inhibitor (PPI) therapy has been recommended as an initial clinical approach for 
      treating GERP. However, PPI use may lead to some health problems. The 
      Gastroesophageal Reflux Disease Questionnaire (GerdQ) may represent a noninvasive 
      and cost-effective approach for avoiding PPI misuse and for identifying the 
      appropriate patients for the PPI trial test. The aim of this pilot study was to 
      prospectively evaluate the association between GerdQ scores and PPI response in 
      patients with coronary artery disease (CAD) and GERP to determine whether the 
      GerdQ predicts the PPI response in patients with CAD and GERP and to further 
      validate the clinical application value of the GerdQ. A total of 154 consecutive 
      patients with potential GERP were recruited to complete a GerdQ with subsequent 
      PPI therapy. Based on the PPI trial result, patients were divided into a 
      PPI-positive response group and a PPI-negative response group. The difference in 
      the GerdQ scores between the two groups was assessed. The receiver operating 
      characteristic (ROC) curve of GerdQ score was drawn according to the PPI response 
      as the gold standard. The ability of GerdQ to predict the PPI response was 
      assessed. A total of 96 patients completed the entire study; 62 patients (64.6%) 
      were assigned to the PPI-positive response group, and 34 patients (35.4%) to the 
      PPI-negative response group. The GerdQ score of the PPI-positive response group 
      (8.11 +/- 3.315) was significantly higher than that of the PPI-negative response 
      group (4.41 +/- 2.743), and the difference was statistically significant (t = 
      5.863, P = 0.000). The ROC curve was drawn according to a PPI response assessment 
      result with a score above 2 as the gold standard. The area under curve was 0.806. 
      When the critical value of GerdQ score was 7.5, Youden index was up to 0.514, the 
      diagnostic sensitivity was 0.661, and the diagnostic specificity was 0.853. A 
      GerdQ score greater than 7.5 better predicts the response to the PPI trial 
      therapy. There is a strong association between the GerdQ score and the response 
      to PPI therapy. Higher GerdQ scores were predictive of a positive PPI response in 
      CAD patients with GERP. The GerdQ may be a reasonable screening tool for GERP in 
      patients with CAD who are prepared to accept PPI therapy.
CI  - (c) 2015 International Society for Diseases of the Esophagus.
FAU - He, S
AU  - He S
AD  - Department of Gastroenterology, Suining Central Hospital, Suining, Sichuan, 
      China.
FAU - Liu, Y
AU  - Liu Y
AD  - Department of Cardiology, Suining Central Hospital, Suining, Sichuan, China.
FAU - Chen, Y
AU  - Chen Y
AD  - Department of Gastroenterology, Suining Central Hospital, Suining, Sichuan, 
      China.
FAU - Tang, Y
AU  - Tang Y
AD  - Department of Gastroenterology, Suining Central Hospital, Suining, Sichuan, 
      China.
FAU - Xu, J
AU  - Xu J
AD  - Department of Gastroenterology, Suining Central Hospital, Suining, Sichuan, 
      China.
FAU - Tang, C
AU  - Tang C
AD  - Department of Cardiology, Suining Central Hospital, Suining, Sichuan, China.
LA  - eng
PT  - Journal Article
DEP - 20150227
PL  - United States
TA  - Dis Esophagus
JT  - Diseases of the esophagus : official journal of the International Society for 
      Diseases of the Esophagus
JID - 8809160
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Chest Pain/diagnosis/drug therapy/etiology
MH  - Coronary Artery Disease/*complications
MH  - Drug Monitoring/methods
MH  - Esophageal pH Monitoring/methods
MH  - Female
MH  - *Gastroesophageal Reflux/complications/diagnosis/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Preference
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - *Proton Pump Inhibitors/administration & dosage/adverse effects
MH  - ROC Curve
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Gastroesophageal Reflux Disease Questionnaire
OT  - coronary artery disease
OT  - gastroesophageal reflux
OT  - noncardiac chest pain
OT  - proton pump inhibitor
EDAT- 2015/02/28 06:00
MHDA- 2017/03/18 06:00
CRDT- 2015/02/28 06:00
PHST- 2015/02/28 06:00 [entrez]
PHST- 2015/02/28 06:00 [pubmed]
PHST- 2017/03/18 06:00 [medline]
AID - 10.1111/dote.12329 [doi]
PST - ppublish
SO  - Dis Esophagus. 2016 May;29(4):367-76. doi: 10.1111/dote.12329. Epub 2015 Feb 27.